Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, two part trial (A and B), open label study of Atezolizumab for patients
with non-small cell lung cancer (NSCLC) or an advanced solid tumor that has been previously
treated with a PD-1 inhibitor (either nivolumab or pembrolizumab).